Select Page

Press

  • EpiVax is proud to support "Hope is a Vaccine" awards

    Posted on November 27, 2011 by Annie De Groot
    Access to treatment is the main reason that AIDS-related deaths have tumbled in recent years. That’s something 2011 Hope Is a Vaccine Award winners (International Category), Julio Montaner and Myron Cohen, would have predicted . . .according to UNAIDS, “An estimated 700,000 AIDS-related deaths were estimated to have been averted in 2010 alone . . ...
    Read more
  • Westin Immunogenicity Seminar September 27 2011, Tokyo, Japan

    Westin Immunogenicity Seminar September 27 2011, Tokyo, Japan

    Posted on September 5, 2011 by Annie De Groot
    Westin Immunogenicity Seminar 2011 Tuesday, September 27, 2011 9:45 am – 6:10 pm Kiri Room The Westin Tokyo 1-4-1 Mita Meguro-ku, Tokyo 153-8580 Japan Speakers: Annie De Groot M.D. Director and Professor, Institute of Immunology and Informatics,University of Rhode Island and CEO/CSO EpiVax; Frances Terry, Immunoinformatics / Bioinformatics Specialist, EpiVax, Inc. Keizo Yoshida Ph.D., EpiVax Asia   9: 00 – 9 :45  AM Registration / Breakfast 9: ...
    Read more
  • Any Prime-Boost Mix of Injected or Spray Flu Vaccine Shields Toddlers

    Posted on August 19, 2011 by Anthony Marcello
    Broadest Immune Response from Nasal Spray Vaccine, NIH-Funded Study Finds (The following is an excerpt from an article published by the National Institute of Allergy and Infectious Diseases on August 16, 2011. Featured in the article is Dr. Daniel Hoft, who collaborates with EpiVax on vaccine research. In addition, Dr. Hoft gave a lecture titled “Romana’s Sign ...
    Read more
  • Clinica Esperanza/Hope Clinic celebrates 1st Anniversary

    Posted on May 30, 2011 by Annie De Groot
    According to EpiVax CEO De Groot, who is the volunteer Medical Director at Clinica Esperanza, improving access to care for uninsured patients will reduce the morbidity and mortality among the uninsured from preventable and treatable health problems. Dr. Peter Simon, medical director at the R.I. Department of Health, described the wide range of languages and ...
    Read more
  • Bringing hope and healthcare to the uninsured

    Posted on May 15, 2011 by Annie De Groot
    “We were interested in providing culturally sensitive care to ununinsured patients in the patient’s own language,” says Dr. Annie De Groot, EpiVax CEO, who is also cofounder and volunteer Medical Director of the new clinic. Last year, the clinic’s first permanent location opened.
    Read more
  • Immunogenicity and Vaccine Talks 2011

    Immunogenicity and Vaccine Talks 2011

    Posted on March 26, 2011 by Annie De Groot
    Come hear the latest updates on better proteins and vaccines by design – See our list of speaking engagements and appearances here:
    Read more
  • Expression of concern to our Japanese colleagues and friends

    Expression of concern to our Japanese colleagues and friends

    Posted on March 16, 2011 by Annie De Groot
    To our dear friends and colleagues in Japan We have been following the events that are unfolding in Japan with great concern. Our hearts go out to the victims of the great earthquake and tsunami of March 11, 2011. Please accept our sincere condolences for any loss that you and your companies may have experienced. We apologize ...
    Read more
  • Agenda for Immunogenicity Determinants and Correlates Conference

    Agenda for Immunogenicity Determinants and Correlates Conference

    Posted on March 5, 2011 by Annie De Groot
    Agenda for Immunogenicity Determinants and Correlates Conference – Valid as of March 05, 2011
    Read more
  • 4th Tregitope Update - Open Meeting May 11 2011

    4th Tregitope Update – Open Meeting May 11 2011

    Posted on February 13, 2011 by Annie De Groot
    Tregitopes are small peptidic regulatory T-cell epitopes derived from human immunoglobulins that activate regulatory T cells (Tregs). Tregitope therapy has broad-reaching implications, offering new treatments for autoimmune diseases (e.g. type 1 juvenile diabetes, multiple sclerosis, rheumatoid arthritis, and lupus), allergies, and transplantation rejection. In previous meetings, the members of the Tregitope Collaborators team have demonstrated ...
    Read more
  • Immunogenicity Determinants and Correlates: Registration Now Open

    Immunogenicity Determinants and Correlates: Registration Now Open

    Posted on February 13, 2011 by Annie De Groot
    Immunogenicity: Determinants and Correlates is a non-commercial meeting, sponsored by the Institute for Immunology and Informatics and organized by individuals from a wide range of backgrounds including industry and academic settings. The current agenda, confirmed speakers, and the registration website are now posted for your review.
    Read more
  • Anti-Cancer Vaccine Progress at EpiVax

    Posted on February 2, 2011 by Annie De Groot
    New study from Rhode Island Hospital identifies a potential vaccine to prevent gastritis, ulcer disease, gastric cancer HelicoVax vaccine targets H. pylori PROVIDENCE, R.I. – A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island (URI) and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has ...
    Read more
  • Immunogenicity: Determinants and Correlates

    Immunogenicity: Determinants and Correlates

    Posted on January 25, 2011 by Annie De Groot
    SAVE THE DATE May 9, 10 and 11 1st Immunogenicity – Determinates and Correlates Providence, RI
    Read more
  • Immunogenicity, Tregitopes and Tolerance 2011

    Immunogenicity, Tregitopes and Tolerance 2011

    Posted on December 21, 2010 by Annie De Groot
    Annie De Groot, EpiVax CEO will be speaking at the following conferences. Please click on the links for more information. We look forward to meeting you there! Invited Speaker. Regulating Immune Response in Biologics – A Paradigm- Shifting Solution. Session: Immunogenicity Issues. 2nd Annual Advancing Biologics from the Lab to the Clinic, Amsterdam, Netherlands. January 25-26, ...
    Read more
  • EpiVax CEO Named Local Hero by Bank of America

    Posted on November 21, 2010 by Annie De Groot
    EpiVax CEO Annie De Groot was one of 10 individuals honored by the Bank of America Neighborhood Excellence Initiative’s Local Heroes program for her volunteerism and civic engagement on November 2, 2010.
    Read more
  • EpiVax Receives 4th Highest Federal Grant for Healthcare Therapies in the State

    Posted on November 8, 2010 by Anthony Marcello
    As part of the Therapeutic Discovery Program included in the Affordable Care Act, EpiVax has been awarded two federal grants totaling $252,722. The U.S. Department of Health and Human Services and the U.S. Treasury has awarded a total of $4.6 million in federal grants to fourteen Rhode Island biotechnology companies; EpiVax received the fourth highest ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here